Healios KK (TSE:4593) Cyclically Adjusted Revenue per Share: 円2.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4593 Healios KK TSE:4593
50 GF Score
Price 円226.00
GF Value 円56.45
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Healios KK Cyclically Adjusted Revenue per Share?

Healios KK TSE:4593 -7.00% 50 Cyclically Adjusted Revenue per Share is 円2.00 as of Mar. 2026. GuruFocus rates TSE:4593 with a GF Score™ of 50/100 and a GF Value™ of 円56.45 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Healios KK's adjusted revenue per share for the three months ended in Mar. 2026 was 円0.064. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円2.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Healios KK's average Cyclically Adjusted Revenue Growth Rate was -9.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-28), Healios KK's current stock price is 円226.00. Healios KK's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円2.00. Healios KK's Cyclically Adjusted PS Ratio of today is 113.00.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Healios KK was 330.19. The lowest was 76.00. And the median was 157.47.


Healios KK  (TSE:4593) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Healios KK's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=226.00/2.00
=113.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Healios KK was 330.19. The lowest was 76.00. And the median was 157.47.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Healios KK Cyclically Adjusted Revenue per Share Related Terms


Healios KK Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Healios KK's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healios KK Cyclically Adjusted Revenue per Share Chart

Healios KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 2.24 2.06

Healios KK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.21 2.12 2.09 2.06 2.00

TSE:4593 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Healios KK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Healios KK Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Healios KK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Healios KK's Cyclically Adjusted PS Ratio falls into.


TSE:4593
50GF Score
Healios KK TSE:4593
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healios KK Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Healios KK's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.064/112.7000*112.7000
=0.064

Current CPI (Mar. 2026) = 112.7000.

Healios KK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.522 98.100 0.600
201609 0.389 98.000 0.447
201612 0.487 98.400 0.558
201703 0.486 98.100 0.558
201706 0.153 98.500 0.175
201709 0.000 98.800 0.000
201712 0.000 99.400 0.000
201803 0.000 99.200 0.000
201806 0.000 99.200 0.000
201809 0.000 99.900 0.000
201812 0.000 99.700 0.000
201903 2.212 99.700 2.500
201906 -0.690 99.800 -0.779
201909 0.138 100.100 0.155
201912 0.137 100.500 0.154
202003 0.136 100.300 0.153
202006 0.136 99.900 0.153
202009 0.136 99.900 0.153
202012 0.116 99.300 0.132
202103 0.159 99.900 0.179
202106 0.193 99.500 0.219
202109 0.213 100.100 0.240
202112 0.148 100.100 0.167
202203 0.199 101.100 0.222
202206 0.199 101.800 0.220
202209 0.141 103.100 0.154
202212 0.949 104.100 1.027
202303 0.110 104.400 0.119
202306 1.571 105.200 1.683
202309 0.100 106.200 0.106
202312 0.094 106.800 0.099
202403 0.120 107.200 0.126
202406 5.521 108.200 5.751
202409 0.387 108.900 0.401
202412 0.203 110.700 0.207
202503 0.396 111.100 0.402
202506 0.220 111.700 0.222
202509 0.181 112.000 0.182
202512 0.232 113.000 0.231
202603 0.064 112.700 0.064

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円2.00 mean?
Healios KK (TSE:4593) has a Cyclically Adjusted Revenue per Share of 円2.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Healios KK and its competitors.
Is Healios KK's Cyclically Adjusted Revenue per Share too high?
Healios KK's current Cyclically Adjusted Revenue per Share is 円2.00. Overall, Healios KK has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Healios KK's Cyclically Adjusted Revenue per Share of 円2.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Healios KK and its competitors. Healios KK's current Cyclically Adjusted Revenue per Share is 円2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (TSE:4593) is currently considered Significantly Overvalued. The stock's GF Value™ is 円56.45, compared to a current price of 円226.00 — trading 300.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円2.00. Healios KK's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Healios KK (TSE:4593), the current Cyclically Adjusted Revenue per Share is 円2.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healios KK (TSE:4593) Overvalued in 2026?

Based on GuruFocus' analysis, Healios KK stock appears to be overvalued. The current stock price of 円226.00 is trading 300.4% above its estimated GF Value™ of 円56.45. GuruFocus considers Healios KK to be Significantly Overvalued.

Key valuation signals for TSE:4593:

  • Cyclically Adjusted Revenue per Share: 円2.00
  • GF Value™: 円56.45 vs. price of 円226.00 (300.4% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the TSE:4593 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Healios KK Business Description

Other Exchanges HLOSF:USA6VX:Germany
Address 1-1-2 Yurakucho, Hibiya Mitsui Tower 12Floor, Work Styling, Chiyoda-ku, Tokyo, JPN, 100-0006
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
50GF Score

Get the complete analysis for TSE:4593

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円226.00
Price
円56.45
GF Value